Malignant Melanoma Clinical Trial
Official title:
High Intensity Interval Training (HIIT) on Stationary Bike With and Without Compression Stockings for Patients With Cancer-related Lymphedema in the Lower Limbs - a Feasibility Study
Verified date | November 2018 |
Source | Herlev and Gentofte Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the study is to explore the feasibility and safety of High Intensity Interval
Training on a stationary bike for patients with lymphedema in the lower limbs and the role of
compression garments during exercise.
The design of the study is a cross-over randomized clinical trial. Participants will be
randomized into two groups. Both will perform two separate exercise sessions.Group A will
perform the first exercise with compression garment and the second session without
compression garment, with wash-out period of 1 week between sessions. Group B will perform
the exercise sessions in the opposite order.
Status | Completed |
Enrollment | 20 |
Est. completion date | November 13, 2018 |
Est. primary completion date | November 13, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - unilateral or bilateral lymphedema in the lower limbs - secondary lymphedema - wears custommade compression stockings during daytime - lymphedema in stage 1, 2A or 2B (Classification from the International Society of Lymphology) - legally competent persons with ability to read and understand Danish. Exclusion Criteria: - inability to perform the intervention, as assessed by the person performing inclusion. - lymphedema in stage 0 or 3 (Classification from the International Society of Lymphology) - ongoing complete decongestive lymphedema therapy - untreated erysipelas - ongoing oncologic treatment: chemotherapy, radiation, immune therapy, - known metastatic cancer - comorbidities e.g. deep venenous thrombosis, serious heart disease, renal insufficiency |
Country | Name | City | State |
---|---|---|---|
Denmark | Department of Physiotherapy and Occupational Therapy, Herlev and Gentofte Hospital | Herlev |
Lead Sponsor | Collaborator |
---|---|
Herlev and Gentofte Hospital | University of Copenhagen |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility rate | Number of invited eligible participants enrolled in the study | After 3 months | |
Primary | Completion rate | Number of enrolled participants completing both interventions | After 3 months | |
Secondary | Participant satisfaction | At the end of the study participation, data describing participant satisfaction will be collected to answers questions on acceptability. All participants will be given a questionnaire and will be asked to rank various aspects of the intervention including exercising without compression garments "as not at all satisfied", "not very satisfied", "somewhat satisfied" or "very satisfied". Feasibility will be defined as >75% of participants reporting they are "very" or "somewhat satisfied" with the intervention. | Week 2 | |
Secondary | Change in pain related to lymphedema | Participant-reported pain measured on a numeric range scale 0-10, "0" indicating no pain and "10" as worst imaginable pain. Measurements will be made immediately before and after each exercise session. | Hour 0 and 1 post each exercise sessions | |
Secondary | Change in tension related to lymphedema | Participant-reported tension measured on a numeric range scale 0-10, "0" indicating no tension and "10" worst imaginable tension. Measurements will be made immediately before and after each exercise session. | Hour 0 and 1 post each exercise sessions | |
Secondary | Change in heaviness related to lymphedema | Participant-reported heaviness measured on a numeric range scale 0-10, "0" indicating no heaviness and "10" worst imaginable heaviness. Measurements will be made immediately before and after each exercise session. | Hour 0 and 1 post each exercise sessions | |
Secondary | Change in volume of lower limbs | Tape Measurements(cm) at 8 cm intervals, converted to volume (ml) by formula of truncated cone. Measurements will be made immediately before and after each exercise session | Hour 0 and hour 1 post each exercise sessions | |
Secondary | Change in extracellular fluid in the lower limbs | Bioimpedance Spectroscopy. Measurements will be made immediately before and after each exercise session. | Hour 0 and hour 1 post each exercise session | |
Secondary | Change in weight of the lower limbs | Dual Energy Xray Absorptiometry, a full body scan is performed. Afterwards regions of interest is marked and weight of each lower limb calculated. Measurements will be made immediately before and after each exercise session. | Hour 0 and hour 1 post each exercise session |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04229277 -
Fast Track Diagnosis of Skin Cancer by Advanced Imaging
|
N/A | |
Active, not recruiting |
NCT04074096 -
Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis
|
Phase 2 | |
Completed |
NCT02935790 -
Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab
|
Phase 1 | |
Recruiting |
NCT05478876 -
Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract
|
N/A | |
Completed |
NCT01211262 -
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
|
Phase 1 | |
Recruiting |
NCT03649529 -
Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy
|
Early Phase 1 | |
Completed |
NCT03278665 -
4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy
|
Phase 1/Phase 2 | |
Completed |
NCT04452214 -
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
|
Phase 1 | |
Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01455259 -
Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00978913 -
Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma
|
Phase 1 | |
Completed |
NCT00232726 -
Clinical Study of Previously Untreated Patients With Malignant Melanoma
|
Phase 2 | |
Completed |
NCT00336986 -
Efficacy Study of IL-21 to Treat Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00350597 -
GM-CSF as Adjuvant Therapy of Melanoma
|
Phase 2 | |
Completed |
NCT02523313 -
Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED
|
Phase 2 | |
Completed |
NCT03545334 -
Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study
|
N/A | |
Completed |
NCT04253574 -
Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma
|
||
Completed |
NCT00179608 -
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
|
Phase 1 | |
Terminated |
NCT00104884 -
FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
|
Phase 2 | |
Recruiting |
NCT04593485 -
Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract
|
Phase 2 |